PAX Financial Group’s Fulgent Genetics FLGT Stock Holding History

PAX Financial Group’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,500	Closed	-$406K	–	183
2022 Q1	$406K	Buy	+6,500	New	+$428K	0.09%	151

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PAX Financial Group's FLGT Position: Q2 2022 in Review

PAX Financial Group sold out of Fulgent Genetics (FLGT) in Q2 2022, closing a stake of 6,500 shares — an estimated $406K sold.

PAX Financial Group first reported a position in FLGT in Q1 2022 and held it in 1 quarter. The position peaked at $406K in Q1 2022. 262 funds tracked by Wall St. Rank hold FLGT as of Q2 2022.

PAX Financial Group reported no remaining Fulgent Genetics position as of Q2 2022 after selling out during the quarter.
PAX Financial Group sold 6,500 Fulgent Genetics shares in Q2 2022, an estimated $406K.
PAX Financial Group first reported a position in Fulgent Genetics in Q1 2022 and held it in 1 quarter.
PAX Financial Group's Fulgent Genetics position peaked at $406K in Q1 2022.
262 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2022.

Based on PAX Financial Group's 13F filing for Q2 2022, filed 9 Aug 2022.